Kestra Medical Technologies (Nasdaq: KMTS) will report third quarter fiscal 2026 results on Tuesday, March 17, 2026 with a conference call at 4:30 p.m. ET. A live and archived webcast will be available in the investor relations Events section; participants are asked to register 10 minutes early.
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
Q2 FY2026 Revenue:$22.6MRevenue Growth:53% YoYASSURE Prescriptions:4,696+5 more
Gross Margin50.6% vs 39.6%Q2 FY2026 vs prior-year quarter gross margin
GAAP Net Loss$32.8MQ2 FY2026 GAAP net loss
FY2026 Revenue Guidance$91M, +52% vs FY25Raised full-year FY2026 revenue outlook
Cash & Equivalents$175MBalance as of Oct 31, 2025
Public Offering Proceeds$138,000,000Upsized primary offering of 6,000,000 shares at $23.00
Market Reality Check
Price:$22.75Vol:Volume 259,265 is roughly...
normal vol
$22.75Last Close
VolumeVolume 259,265 is roughly in line with the 251,664 share 20-day average.normal
TechnicalPrice 22.75 is trading slightly above the 22.19 200-day MA.
Peers on Argus
Peers show mixed moves with no clear sector trend: EMBC (-0.3%), BLFS (-4.9%), S...
Peers show mixed moves with no clear sector trend: EMBC (-0.3%), BLFS (-4.9%), STAA (-2.46%) vs PLSE (+4.84%) and ATRC (+1.68%). KMTS’s -2.28% move appears stock-specific.
Set Q2 FY2026 earnings date and call details for investors.
Pattern Detected
Prior “earnings date” scheduling news saw a strong positive reaction, suggesting investors have treated timing announcements as meaningful catalysts before.
Recent Company History
This announcement sets the date for Kestra’s Q3 FY2026 results on March 17, echoing the prior Q2 FY2026 earnings date notice on December 3, 2025, which preceded a 12.21% gain over 24 hours. Around that period, Kestra also reported strong Q2 FY2026 fundamentals, including rapid revenue growth and margin expansion, plus a capital raise that bolstered liquidity. Together, these events frame a backdrop of aggressive growth and active investor engagement heading into the next earnings release.
Historical Comparison
+12.2% avg move · Past earnings-date news (1 event) saw an average move of 12.21%, indicating that simple scheduling u...
earnings date
+12.2%
Average Historical Moveearnings date
Past earnings-date news (1 event) saw an average move of 12.21%, indicating that simple scheduling updates have previously acted as notable catalysts for KMTS.
Repeated quarterly earnings-date announcements reflect a consistent cadence of financial disclosure as Kestra advances through FY2026.
Market Pulse Summary
This announcement sets the Q3 FY2026 earnings release for March 17 with a conference call at 4:30 p....
Analysis
This announcement sets the Q3 FY2026 earnings release for March 17 with a conference call at 4:30 p.m. ET, continuing Kestra’s regular reporting cadence. Investors will likely focus on whether prior trends—Q2 FY2026 revenue of $22.6M, 53% YoY growth, and gross margin of 50.6%—remain intact, and how losses such as the $32.8M GAAP net loss evolve. The previously raised FY2026 revenue guidance of $91M is a key benchmark to monitor.
Key Terms
wearable cardioverter defibrillator, ambulatory blood pressure monitoring, rule 10b5-1 trading plan, form 144, +4 more
8 terms
wearable cardioverter defibrillatormedical
"into the ASSURE Wearable Cardioverter Defibrillator (WCD) ecosystem."
A wearable cardioverter defibrillator is a lightweight, portable device worn on the body that continuously monitors heart rhythm and automatically or manually delivers an electric shock to stop a life‑threatening irregular heartbeat. Think of it as a mobile airbag for the heart: it protects high‑risk patients when a permanent implant isn’t suitable. Investors watch sales, reimbursement rules, clinical evidence and guideline use because those factors drive adoption, recurring revenue and liability exposure.
ambulatory blood pressure monitoringmedical
"cuffless 24-hour ambulatory blood pressure monitoring (ABPM) into the ASSURE"
Ambulatory blood pressure monitoring is a portable device and process that measures a person’s blood pressure repeatedly over a day and night while they go about normal activities and sleep. Investors care because it gives more reliable, real-world evidence of how treatments or devices affect blood pressure than a single clinic reading, influencing clinical trial results, regulatory decisions, reimbursement and the market demand for monitoring products — like using a continuous camera instead of a single snapshot.
rule 10b5-1 trading planregulatory
"sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
form 144regulatory
"shareholder Brian Webster has filed a Form 144 notice to sell 15,000"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
schedule 13gregulatory
"filed a Schedule 13G reporting a significant passive ownership position"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
schedule 13g/aregulatory
"filed a Schedule 13G/A reporting a significant ownership position"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
post-approval studymedical
"announces primary results from the ACE‑PAS post‑approval study, presented"
A post-approval study is a research program regulators require or companies choose to run after a drug or medical device is already approved and sold, to track real-world safety, longer-term effectiveness, or performance in broader patient groups. Investors care because results can change product labels, sales forecasts, or trigger additional costs and restrictions—think of it as a warranty-era check that can alter a product’s market value and legal risk.
regulation fdregulatory
"filed an 8‑K under Regulation FD, furnishing a press release titled"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
AI-generated analysis. Not financial advice.
KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it will report third quarter fiscal 2026 financial results on Tuesday, March 17. Management will host a corresponding conference call at 4:30 p.m. Eastern Time.
A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call.
About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
FAQ
When will Kestra Medical Technologies (KMTS) report Q3 fiscal 2026 results?
Kestra Medical Technologies will report third quarter fiscal 2026 results on Tuesday, March 17, 2026. According to the company, management will host a conference call and provide a live and archived webcast in the investor relations Events section.
What time is the KMTS conference call for the March 17, 2026 earnings report?
The conference call is scheduled for 4:30 p.m. Eastern Time on March 17, 2026. According to the company, a live and archived webcast will also be available and participants should register on the website 10 minutes before start.
Where can investors access the Kestra Medical Technologies (KMTS) webcast for the March 17 call?
Investors can access the live and archived webcast in the investor relations Events section on the company website. According to the company, the webcast will be posted for live listening and later archived for on-demand review.
Do participants need to register to join the KMTS March 17, 2026 conference call?
Participants are encouraged to register on the company website 10 minutes prior to the conference call. According to the company, early registration helps ensure timely access to the live webcast and conference call line.
Will Kestra Medical Technologies (KMTS) provide an archived replay of the March 17 earnings call?
Yes, an archived replay will be available in the investor relations Events section after the call. According to the company, the webcast will be archived for later listening and investor review following the live conference call.
